Investigational Drug for Advanced Salivary Gland Cancer (Adenoid Cystic Carcinoma)
Part of Cancer clinical trials.
This clinical trial studies an experimental drug called AZD8205 for people with a specific type of advanced adenoid cystic carcinoma (ACC). ACC is a rare cancer that usually starts in the salivary glands. The trial aims to see if the drug can shrink tumors or slow the disease, and it's for those whose cancer has spread or come back and fits certain molecular features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced (cannot be removed with surgery), recurrent, or spread to other parts of the body.
- Your tumor must have certain features, such as a specific gene change (NOTCH mutation), a particular appearance under the microscope (solid type), or a negative test for a protein called TP63.
- You must be able to perform daily activities with little or no help (ECOG performance status 0 or 1).
- You must not have had more than 2 prior chemotherapy or antibody-drug conjugate treatments, and you cannot have had any drug that targets B7-H4 or topoisomerase 1 inhibitor.
- You must have completed a waiting period after any previous cancer treatment (e.g., at least 21 days for chemotherapy, 28 days for radiation or major surgery).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called REM-422 for people with adenoid cystic carcinoma (ACC) that has spread, come back, or cannot be removed by surgery. The study has two parts: an early part for people with advanced ACC and a later part for those with a specific genetic change (MYB biomarker) in their tumor. The goal is to see if REM-422 can slow or stop cancer growth.
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
This Phase 1/2 study tests how well CB-103 works in people with advanced, hard-to-treat adenoid cystic carcinoma that has a specific NOTCH pathway change. The study also looks at whether combining CB-103 with either lenvatinib or abemaciclib is safe and effective for different groups of patients.
This trial tests a combination of a targeted antibody-drug and focused radiation for people with advanced or recurrent salivary gland cancer that has spread. It aims to see if this treatment can help control the disease when standard treatments have stopped working.
This study uses advanced tests on tissue and blood samples to understand why adenoid cystic carcinoma (a type of head and neck cancer) spreads. It aims to find new clues that may help improve future treatments.
This trial tests a new drug called sacituzumab tirumotecan for people with recurrent or metastatic adenoid cystic carcinoma or papillary thyroid carcinoma. The drug works by targeting a protein on cancer cells to deliver treatment directly, which may help shrink tumors or slow their growth.
Hear when a new Adenoid Cystic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.